Skip to content

Study · Not a test of the peptide alone · 2015

9 results

Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes.

Kimura T, Kaneto H, Shimoda M, Hirukawa H, Okauchi S, Kohara K, Hamamoto S, Tawaramoto K, Hashiramoto M, Kaku K

Molecular and cellular endocrinology24 Nov 2014Cited by 53 (Europe PMC)

PMID25463759 (opens in a new tab)DOI10.1016/j.mce.2014.11.018 (opens in a new tab)PepBankPUB-25463759
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The aim was to compare the protective effects of pioglitazone (PIO) and/or liraglutide (LIRA) on β-cells with the progression of diabetes. Male db/db mice were treated with PIO and/or LIRA for 2 weeks in an early and advanced stage. In an early stage insulin biosynthesis and secretion were markedly increased by PIO and LIRA which was not observed in an advanced stage. In concomitant with such phenomena, expression levels of various β-cell-related factors were up-regulated by PIO and LIRA only in an early stage. Furthermore, β-cell mass was also increased by the treatment only in an early stage. Although there was no difference in apoptosis ratio between the two stages, β-cell proliferation was augmented by the treatment only in an early stage. In conclusion, protective effects of pioglitazone and/or liraglutide on β-cells were more powerful in an early stage of diabetes compared to an advanced stage.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In db/db mice, treatment with pioglitazone and/or liraglutide markedly increased insulin biosynthesis and secretion in an early stage of diabetes.

    In plain wordsIn mice with early diabetes, pioglitazone and/or liraglutide treatment raised insulin production and release.

    Peptide
    Liraglutide
    Outcome
    IncreaseInsulin biosynthesis and secretion, early stage
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    In an early stage insulin biosynthesis and secretion were markedly increased by PIO and LIRA which was not observed in an advanced stage.
    1 context sentence
    Summary · context
    Male db/db mice were treated with PIO and/or LIRA for 2 weeks in an early and advanced stage.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In db/db mice, the increase in insulin biosynthesis and secretion with pioglitazone and/or liraglutide was not seen in an advanced stage of diabetes.

    In plain wordsIn mice with advanced diabetes, pioglitazone and/or liraglutide treatment did not raise insulin production and release.

    Peptide
    Liraglutide
    Outcome
    No significant changeInsulin biosynthesis and secretion, advanced stage
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    In an early stage insulin biosynthesis and secretion were markedly increased by PIO and LIRA which was not observed in an advanced stage.
    1 context sentence
    Summary · context
    Male db/db mice were treated with PIO and/or LIRA for 2 weeks in an early and advanced stage.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In db/db mice, pioglitazone and/or liraglutide up-regulated expression of various beta-cell-related factors in an early stage of diabetes.

    In plain wordsIn mice with early diabetes, pioglitazone and/or liraglutide treatment raised the activity of genes linked to beta cells.

    Peptide
    Liraglutide
    Outcome
    IncreaseBeta-cell-related factor expression, early stage
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Islet protection · Endocrine and hormones

    Source sentences

    Summary
    In concomitant with such phenomena, expression levels of various β-cell-related factors were up-regulated by PIO and LIRA only in an early stage.
    1 context sentence
    Summary · context
    Male db/db mice were treated with PIO and/or LIRA for 2 weeks in an early and advanced stage.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In db/db mice, expression of beta-cell-related factors was up-regulated by pioglitazone and/or liraglutide only in an early stage, not in an advanced stage.

    In plain wordsIn mice with advanced diabetes, pioglitazone and/or liraglutide treatment did not raise the activity of genes linked to beta cells.

    Peptide
    Liraglutide
    Outcome
    No significant changeBeta-cell-related factor expression, advanced stage
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Islet protection · Endocrine and hormones

    Source sentences

    Summary
    In concomitant with such phenomena, expression levels of various β-cell-related factors were up-regulated by PIO and LIRA only in an early stage.
    1 context sentence
    Summary · context
    Male db/db mice were treated with PIO and/or LIRA for 2 weeks in an early and advanced stage.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In db/db mice, pioglitazone and/or liraglutide increased beta-cell mass in an early stage of diabetes.

    In plain wordsIn mice with early diabetes, pioglitazone and/or liraglutide treatment increased the mass of insulin-making beta cells.

    Peptide
    Liraglutide
    Outcome
    IncreaseBeta-cell mass, early stage
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Islet protection · Endocrine and hormones

    Source sentences

    Summary
    Furthermore, β-cell mass was also increased by the treatment only in an early stage.
    1 context sentence
    Summary · context
    Male db/db mice were treated with PIO and/or LIRA for 2 weeks in an early and advanced stage.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In db/db mice, beta-cell mass was increased by pioglitazone and/or liraglutide only in an early stage, not in an advanced stage.

    In plain wordsIn mice with advanced diabetes, pioglitazone and/or liraglutide treatment did not increase the mass of beta cells.

    Peptide
    Liraglutide
    Outcome
    No significant changeBeta-cell mass, advanced stage
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Islet protection · Endocrine and hormones

    Source sentences

    Summary
    Furthermore, β-cell mass was also increased by the treatment only in an early stage.
    1 context sentence
    Summary · context
    Male db/db mice were treated with PIO and/or LIRA for 2 weeks in an early and advanced stage.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 07AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In db/db mice, there was no difference in the beta-cell apoptosis ratio between the early and advanced stages.

    In plain wordsIn mice, the rate of beta-cell death did not differ between early and advanced diabetes.

    Peptide
    Liraglutide
    Outcome
    No significant changeBeta-cell apoptosis ratio
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Islet protection · Endocrine and hormones

    Source sentences

    Summary
    there was no difference in apoptosis ratio between the two stages, β-cell proliferation was augmented by the treatment only in an early stage.
    1 context sentence
    Summary · context
    Male db/db mice were treated with PIO and/or LIRA for 2 weeks in an early and advanced stage.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 08AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In db/db mice, pioglitazone and/or liraglutide augmented beta-cell proliferation in an early stage of diabetes.

    In plain wordsIn mice with early diabetes, pioglitazone and/or liraglutide treatment increased beta-cell growth.

    Peptide
    Liraglutide
    Outcome
    IncreaseBeta-cell proliferation, early stage
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Islet protection · Endocrine and hormones

    Source sentences

    Summary
    β-cell proliferation was augmented by the treatment only in an early stage.
    1 context sentence
    Summary · context
    Male db/db mice were treated with PIO and/or LIRA for 2 weeks in an early and advanced stage.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  9. 09AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In db/db mice, beta-cell proliferation was augmented by pioglitazone and/or liraglutide only in an early stage, not in an advanced stage.

    In plain wordsIn mice with advanced diabetes, pioglitazone and/or liraglutide treatment did not increase beta-cell growth.

    Peptide
    Liraglutide
    Outcome
    No significant changeBeta-cell proliferation, advanced stage
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Islet protection · Endocrine and hormones

    Source sentences

    Summary
    β-cell proliferation was augmented by the treatment only in an early stage.
    1 context sentence
    Summary · context
    Male db/db mice were treated with PIO and/or LIRA for 2 weeks in an early and advanced stage.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.